Renal Cell Carcinoma Clinical Trial
Official title:
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
Verified date | September 2011 |
Source | AVEO Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to test the safety and tolerability of tivozanib (AV-951) and Torisel™ given in combination for renal cell cancer. The study will also assess the effects of the combination of tivozanib (AV-951) and Torisel™ on the tumor. Tivozanib (AV-951) is a VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking blood flow to the tumor. Temsirolimus is an mTOR inhibitor which is approved for the treatment of advanced renal cell carcinoma.
Status | Completed |
Enrollment | 28 |
Est. completion date | February 2011 |
Est. primary completion date | November 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - = 18-year-old males or females - Histologically confirmed renal cell carcinoma with a clear cell component - Documented progressive disease - Measurable disease by RECIST criteria - No more than 1 prior VEGF receptor targeted therapy; no prior treatment with temsirolimus or other drugs targeting the mTOR pathway - Karnofsky performance status > 70%; life expectancy = 3 months - Ability to give written informed consent Exclusion Criteria: - Known hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any other component of the temsirolimus formulation - Primary CNS malignancies; active CNS metastases - Hematologic malignancies (including leukemia in any form, lymphoma, and multiple myeloma) - Any of the following hematologic abnormalities: - Hemoglobin < 9.0 g/dL - ANC < 1500 per mm3 - Platelet count < 100,000 per mm3 - Any of the following serum chemistry abnormalities: - Fasting serum cholesterol > 350 mg/dL - Fasting triglycerides > 400 mg/dL - Total bilirubin > 1.5 × ULN - AST or ALT > 2.5 × ULN (or > 5 x ULN in subjects with liver metastasis) - Serum albumin < 3.0 g/dL - Creatine > 1.5 × ULN (or calculated CLCR <50 mL/min/1.73 m2) - Proteinuria > 2.5 g/24 hours or 3+ with urine dipstick - Significant cardiovascular disease, including: - Active clinically symptomatic left ventricular failure - Active hypertension (diastolic blood pressure > 100 mmHg). Subjects with a history of hypertension must have been on stable doses of anti-hypertensive drugs for = 4 weeks - Uncontrolled hypertension: Blood pressure >140/90 mmHg on 2 or more antihypertensive medications - Myocardial infarction within 3 months prior to administration of first dose of study drug - Subjects with delayed healing of wounds, ulcers, and/or bone fractures - Pulmonary hypertension or pneumonitis - Serious/active infection; infection requiring parenteral antibiotics - Inadequate recovery from any prior surgical procedure; major surgical procedure within 6 weeks prior to study entry - Uncontrolled psychiatric disorder, altered mental status precluding informed consent or necessary testing - Inability to comply with protocol requirements - Ongoing hemoptysis or history of clinically significant bleeding - Cerebrovascular accident within 12 months of study entry, or peripheral vascular disease with claudication on walking less than 1 block - Deep venous thrombosis or pulmonary embolus within 6 months of study entry and/or ongoing need for full-dose oral or parenteral anticoagulation - Subjects with a "currently active" second primary malignancy other than non-melanoma skin cancers. Subjects are not considered to have a "currently active" malignancy if they have completed anti-cancer therapy and are considered by their physician to be < 30% risk of relapse. - Pregnant or lactating women - Known concomitant genetic or acquired immune suppression disease such as HIV Prohibited medications: - VEGF receptor (VEGFR) targeted therapy within 4 weeks prior to and during study - Other signal transduction inhibitors, monoclonal antibodies, etc., within 4 weeks prior to and during study - Immunotherapy or biological response modifiers within 4 weeks prior to and during study - Systemic hormonal therapy within 4 weeks prior to and during study, with the exception of: - Hormonal therapy for appetite stimulation or contraception - Nasal, ophthalmic, and topical glucocorticoid preparations - Oral replacement therapy for adrenal insufficiency - Low-dose maintenance steroid therapy for other conditions - Herbal preparations/supplements (except for a daily multivitamin/mineral supplement not containing herbal components) within 2 weeks prior to or during study - Any experimental therapy 4 weeks prior to and during study - Radiotherapy: - At least 2 weeks since prior local radiation therapy (ie, involving <25% of bone marrow) at the time of study entry - At least 4 weeks since prior radiation therapy involving = 25% of bone marrow - Treatment with CYP3A4 inducers or inhibitors during the study |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | The Methodist Hospital Research Institute | Houston | Texas |
United States | UCLA Jonsson Comprehensive Cancer Center | Los Angeles | California |
United States | Nebraska Methodist Hospital | Omaha | Nebraska |
United States | Stanford University | Stanford | California |
United States | H. Lee Moffitt Cancer Center | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
AVEO Pharmaceuticals, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine the safety and tolerability of tivozanib (AV-951) when given in combination with temsirolimus | 4 weeks (1 cycle) | Yes | |
Secondary | To characterize the pharmacokinetic profile of tivozanib (AV-951) and temsirolimus when administered in combination | 8 weeks (2 cycles) | No | |
Secondary | To evaluate the antineoplastic activity of tivozanib (AV-951) and temsirolimus when administered in combination | 8 weeks (2 cycles) | No | |
Secondary | To evaluate the effect of tivozanib (AV-951) and temsirolimus on global and targeted gene expression patterns | 8 weeks (2 cycles) | No | |
Secondary | To determine the maximum tolerated dose (MTD) of tivozanib (AV-951) when administered in combination with temsirolimus | 4 weeks (1 cycle) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04987203 -
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
|
Phase 3 | |
Recruiting |
NCT06391879 -
Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
Completed |
NCT02853344 -
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
|
Phase 2 | |
Terminated |
NCT04088500 -
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT05070637 -
Circulating Tumor Cell Reducing No-touch Nephrectomy
|
N/A | |
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Not yet recruiting |
NCT06049030 -
A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01358721 -
Phase I Biomarker Study (BMS-936558)
|
Phase 1 | |
Active, not recruiting |
NCT04503148 -
Anesthesia and Cancer Study: Renal Cell Carcinoma
|
N/A | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Not yet recruiting |
NCT05808608 -
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03323710 -
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT03052504 -
Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy
|